Furthermore, adjuvant treatment with a recombinant MAGE-A3 protein and AS15 immunostimulant (a liposomal formulation involving a combination of monophosphoryl lipid A and a TLR-9 agonist) did not increase disease-free survival in surgically resected non-small cell lung cancer [14] or in the treatment of surgically treated melanoma patients with stage IIIB or IIIC disease [15]. The gene discussed is MAGEA3; the disease is melanoma.